DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 2,383)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 35 news outlets
twitter: 6 X users

patent: 3 patents

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 16 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 35 news stories from 35 outlets.

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

Ticker Tech, 15 Mar 2022

Results published in Journal of Experimental

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

Spoke, 15 Mar 2022

Results published in Journal of Experimental

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

WSAW-TV, 15 Mar 2022

JERUSALEM, March 15, 2022 /PRNewswire/ -- KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting…

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

WTVM, 15 Mar 2022

JERUSALEM, March 15, 2022 /PRNewswire/ -- KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 31 additional news stories.